Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Aldeyra Therapeutics stock

ALDX
US01438T1060
A111X8

Price

5.04
Today +/-
+0.10
Today %
+2.07 %
P

Aldeyra Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aldeyra Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aldeyra Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aldeyra Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aldeyra Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aldeyra Therapeutics Stock Price History

DateAldeyra Therapeutics Price
11/19/20245.04 undefined
11/19/20244.94 undefined
11/18/20244.70 undefined
11/15/20244.21 undefined
11/14/20244.27 undefined
11/13/20244.69 undefined
11/12/20244.76 undefined
11/11/20245.49 undefined
11/8/20245.52 undefined
11/7/20245.34 undefined
11/6/20245.40 undefined
11/5/20245.27 undefined
11/4/20245.18 undefined
11/1/20245.36 undefined
10/31/20245.26 undefined
10/30/20245.34 undefined
10/29/20245.42 undefined
10/28/20245.62 undefined
10/25/20245.33 undefined
10/24/20245.38 undefined
10/23/20245.50 undefined
10/22/20245.90 undefined

Aldeyra Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aldeyra Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aldeyra Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aldeyra Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aldeyra Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aldeyra Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aldeyra Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aldeyra Therapeutics’s growth potential.

Aldeyra Therapeutics Revenue, EBIT and net profit per share

DateAldeyra Therapeutics RevenueAldeyra Therapeutics EBITAldeyra Therapeutics Net Income
2029e208.15 M undefined0 undefined69.85 M undefined
2028e177.89 M undefined33.39 M undefined86.56 M undefined
2027e116.18 M undefined-3.97 M undefined46.16 M undefined
2026e76.13 M undefined-1.35 M undefined6.29 M undefined
2025e36.35 M undefined-60.52 M undefined-39.54 M undefined
2024e29 M undefined-59.25 M undefined-40.78 M undefined
20230 undefined-42.79 M undefined-37.54 M undefined
20220 undefined-62.68 M undefined-62.02 M undefined
20210 undefined-56.22 M undefined-57.78 M undefined
20200 undefined-34.67 M undefined-37.55 M undefined
20190 undefined-56.5 M undefined-60.83 M undefined
20180 undefined-39.7 M undefined-38.89 M undefined
20170 undefined-22.49 M undefined-22.34 M undefined
20160 undefined-18.7 M undefined-18.7 M undefined
20150 undefined-11.99 M undefined-12.09 M undefined
20140 undefined-7.27 M undefined-9.57 M undefined
20130 undefined-3.68 M undefined1.11 M undefined
20120 undefined-1.12 M undefined-39.13 M undefined
20110 undefined-2.11 M undefined-2.59 M undefined

Aldeyra Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000000283676116177208
--------------28.57111.1152.6352.5917.51
-------------------
0000000000000000000
-2-391-9-12-18-22-38-60-37-57-62-37-40-396468669
-1,850.00-102.56-1,000.0033.3350.0022.2272.7357.89-38.3354.058.77-40.328.11-2.50-115.38666.6786.96-19.77
6.256.256.253.828.6311.3515.9221.6927.1133.9754.0458.4158.94000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aldeyra Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aldeyra Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.31.23.38.527.624.942.993.673.477.9229.8174.3142.82
0000000000000
0000000000000
0000000000000
0000.20.50.211.21.85.236.74.99
0.31.23.38.728.125.143.994.875.283.1232.8181147.81
00001001000200300300400300516.58
0000000000000
0000000000000
0000000000000
0000000000000
0050000020010000000
005000100100200300300300400300516.58
0.31.23.88.728.225.244.195.175.583.4233.2181.3148.33
                         
13.229.238.300000000.10.10.06
001.152.883.598.9139.2225.1247.4296.4500.4507.8514
-15.5-54.4-41.3-46.5-58.6-77.3-99.6-138.5-199.4-236.9-294.7-356.7-394.26
00000000000-0.10
0000000000000
-2.3-25.2-1.96.324.921.639.686.64859.5205.8151.1119.8
00.10.30.30.90.313.10.80.410.11.34
0.40.10.10.91.21.92.25.412.18.410.814.35.78
0000000000000
2.200.10000000000
00.20.10.10.10.10.1003.700.915.15
2.60.40.61.32.22.33.38.512.912.511.815.322.26
026.84.61.21.21.21.2014.511.415.514.90
0000000000000
000.400000000.106.27
026.851.21.21.21.2014.511.415.614.96.27
2.627.25.62.53.43.54.58.527.423.927.430.228.53
0.323.78.828.325.144.195.175.483.4233.2181.3148.33
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aldeyra Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aldeyra Therapeutics's financial health and stability.

Assets

Aldeyra Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aldeyra Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aldeyra Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aldeyra Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-2-2313-5-12-18-22-38-60-37-57-62-37
0000000000000
00000000-10000
000000052-87-30
022-13145582216141611
0000000001,0001,0001,0001,000
0000000000000
-20-1-4-9-15-19-29-44-37-42-56-30
0000000000000
0000-130-10-2318290-2930
0000-120-10-2318290-2930
0000000000000
0010000-114000-1
012102812378194119410
013102812378023411941-1
-------------
0000000000000
-20256-2827-233151-85-1
-2.39-0.78-1.71-4.79-9.4-15.16-19.24-30.12-44.99-37.49-42.57-56.66-30.33
0000000000000

Aldeyra Therapeutics stock margins

The Aldeyra Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aldeyra Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aldeyra Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aldeyra Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aldeyra Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aldeyra Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aldeyra Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aldeyra Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aldeyra Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aldeyra Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aldeyra Therapeutics Margin History

Aldeyra Therapeutics Gross marginAldeyra Therapeutics Profit marginAldeyra Therapeutics EBIT marginAldeyra Therapeutics Profit margin
2029e0 %0 %33.56 %
2028e0 %18.77 %48.66 %
2027e0 %-3.42 %39.73 %
2026e0 %-1.77 %8.27 %
2025e0 %-166.47 %-108.78 %
2024e0 %-204.32 %-140.65 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Aldeyra Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Aldeyra Therapeutics earnings per share therefore indicates how much revenue Aldeyra Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aldeyra Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aldeyra Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aldeyra Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aldeyra Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aldeyra Therapeutics Revenue, EBIT and net profit per share

DateAldeyra Therapeutics Sales per ShareAldeyra Therapeutics EBIT per shareAldeyra Therapeutics Earnings per Share
2029e3.5 undefined0 undefined1.17 undefined
2028e2.99 undefined0 undefined1.45 undefined
2027e1.95 undefined0 undefined0.78 undefined
2026e1.28 undefined0 undefined0.11 undefined
2025e0.61 undefined0 undefined-0.66 undefined
2024e0.49 undefined0 undefined-0.68 undefined
20230 undefined-0.73 undefined-0.64 undefined
20220 undefined-1.07 undefined-1.06 undefined
20210 undefined-1.04 undefined-1.07 undefined
20200 undefined-1.02 undefined-1.11 undefined
20190 undefined-2.08 undefined-2.24 undefined
20180 undefined-1.83 undefined-1.79 undefined
20170 undefined-1.41 undefined-1.4 undefined
20160 undefined-1.65 undefined-1.65 undefined
20150 undefined-1.39 undefined-1.4 undefined
20140 undefined-1.9 undefined-2.51 undefined
20130 undefined-0.59 undefined0.18 undefined
20120 undefined-0.18 undefined-6.26 undefined
20110 undefined-0.34 undefined-0.41 undefined

Aldeyra Therapeutics business model

Aldeyra Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for serious eye and immune system diseases. The company was founded in 2004 by Dr. Tod B. Zimmerman and is headquartered in Lexington, Massachusetts. The history of Aldeyra Therapeutics began with the discovery of a new approach to treating inflammatory diseases. The company identified a new class of compounds known as aldehyde binding agents that help reduce the effects of chronic inflammation. In 2013, Aldeyra went public and raised $15 million to advance the development of its products. Aldeyra Therapeutics' business model focuses on building a portfolio of therapies for serious diseases. The company leverages its expertise in drug discovery, development, and commercialization to develop new therapies targeting rare diseases and unmet clinical needs. Aldeyra Therapeutics is divided into two main areas: ophthalmology and immunology. In the ophthalmology field, the company focuses on developing therapies for the treatment of dry eye, pterygium, conjunctivitis, and other eye diseases. In the immunology field, the company aims to develop therapies for immune-related diseases such as asthma, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and others. One key product of Aldeyra Therapeutics is the drug reproxalap, which was developed to halt the progression of dry eye disease. Reproxalap is an aldehyde binding agent designed to help reduce inflammation, pain, and redness in patients with dry eye. The company plans to conduct further clinical trials for reproxalap to facilitate its submission for approval to the US Food and Drug Administration (FDA). Another product in the immunology field is ADX-1612, an aldehyde binding agent targeting the treatment of asthma. The clinical trials are still in the early phases, but preliminary data provide hope that ADX-1612 could become an important component of asthma therapy in the future. Aldeyra Therapeutics does not work alone. The company has partnerships with other biotech or pharmaceutical companies, such as in the development of therapeutics for rare immunological and eye diseases or the development of diagnostic tests for a specific eye disease. The company hopes that its research and development efforts will ultimately help improve the lives of people with serious diseases. Although there is a risk of setbacks in the development of new therapies, it is hoped that Aldeyra Therapeutics will find new ways in the future to address the unmet needs of patients in need. Aldeyra Therapeutics is one of the most popular companies on Eulerpool.com.

Aldeyra Therapeutics SWOT Analysis

Strengths

Aldeyra Therapeutics Inc has several key strengths that contribute to its success:

  • Diverse pipeline of innovative drug candidates
  • Strong research and development capabilities
  • Experienced leadership team
  • Positive reputation within the pharmaceutical industry
  • Solid financial position

Weaknesses

Aldeyra Therapeutics Inc faces certain weaknesses that could hinder its performance:

  • Relatively small size compared to larger pharmaceutical companies
  • Dependency on external funding for research and development
  • Lack of commercialization experience

Opportunities

Aldeyra Therapeutics Inc can leverage the following opportunities to grow and expand:

  • Increasing demand for novel therapeutics and treatments
  • Global expansion into emerging markets
  • Potential collaborations or partnerships with larger pharmaceutical companies
  • Rising public awareness and investment in biotechnology

Threats

Aldeyra Therapeutics Inc should be aware of the following threats that may impact its operations:

  • Intense competition from established pharmaceutical firms
  • Stringent regulations and compliance requirements
  • Potential delays or setbacks in clinical trials
  • Shifts in market demand and healthcare policies
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aldeyra Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aldeyra Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aldeyra Therapeutics shares outstanding

The number of shares was Aldeyra Therapeutics in 2023 — This indicates how many shares 58.943 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aldeyra Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aldeyra Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aldeyra Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aldeyra Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Aldeyra Therapeutics.

Aldeyra Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.25 -0.25  (0.75 %)2024 Q3
6/30/2024-0.14 -0.28  (-93.64 %)2024 Q2
3/31/2024-0.11 -0.14  (-24.11 %)2024 Q1
12/31/2023-0.14 -0.08  (44.1 %)2023 Q4
9/30/2023-0.24 -0.14  (42.43 %)2023 Q3
6/30/2023-0.32 -0.15  (52.7 %)2023 Q2
3/31/2023-0.3 -0.27  (9.21 %)2023 Q1
12/31/2022-0.32 -0.22  (31.12 %)2022 Q4
9/30/2022-0.35 -0.25  (28.75 %)2022 Q3
6/30/2022-0.32 -0.3  (5.36 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Aldeyra Therapeutics stock

Eulerpool World ESG Rating (EESG©)

43/ 100

🌱 Environment

42

👫 Social

64

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aldeyra Therapeutics shareholders

%
Name
Stocks
Change
Date
15.57658 % Perceptive Advisors LLC9,275,85106/30/2024
9.19482 % Knoll Capital Management, LLC5,475,51606/30/2024
6.28444 % The Vanguard Group, Inc.3,742,386-126,6936/30/2024
5.58640 % BlackRock Institutional Trust Company, N.A.3,326,704251,0106/30/2024
2.68627 % Kennedy Capital Management LLC1,599,673281,5186/30/2024
1.94052 % Brady (Todd C)1,155,580196,3424/9/2024
1.91107 % Geode Capital Management, L.L.C.1,138,043109,8456/30/2024
1.60826 % State Street Global Advisors (US)957,72018,1516/30/2024
1.41322 % Eagle Asset Management, Inc.841,571-126,2446/30/2024
1.12856 % Dimensional Fund Advisors, L.P.672,057-210,1536/30/2024
1
2
3
4
5
...
10

Aldeyra Therapeutics Executives and Management Board

Dr. Todd Brady(51)
Aldeyra Therapeutics President, Chief Executive Officer, Director (since 2005)
Compensation 2.86 M
Dr. Stephen Machatha(46)
Aldeyra Therapeutics Chief Development Officer
Compensation 2.57 M
Mr. Bruce Greenberg(55)
Aldeyra Therapeutics Senior Vice President - Finance, Interim Chief Financial Officer
Compensation 1.48 M
Dr. Richard Douglas(70)
Aldeyra Therapeutics Independent Chairman of the Board
Compensation 225,931
Mr. Martin Joyce(69)
Aldeyra Therapeutics Independent Director
Compensation 198,202
1
2

Aldeyra Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Madrigal Pharmaceuticals Stock
Madrigal Pharmaceuticals
SupplierCustomer0,190,670,890,340,480,53
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer-0,030,700,960,620,460,52
1

Most common questions regarding Aldeyra Therapeutics

What values and corporate philosophy does Aldeyra Therapeutics represent?

Aldeyra Therapeutics Inc represents values of innovation, integrity, and patient-centricity in the field of biopharmaceuticals. With a strong corporate philosophy, the company is committed to advancing novel therapies to address unmet medical needs. Aldeyra Therapeutics Inc offers innovative solutions that aim to improve patients' lives, leveraging cutting-edge scientific research and a dedicated team of professionals. Through their comprehensive approach, the company strives to develop transformative treatments and make a positive impact in the healthcare industry. The core values of Aldeyra Therapeutics Inc drive its mission to deliver effective and safe therapeutic options for patients worldwide.

In which countries and regions is Aldeyra Therapeutics primarily present?

Aldeyra Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Aldeyra Therapeutics achieved?

Aldeyra Therapeutics Inc., a leading biotechnology company, has achieved several significant milestones. The company has made substantial progress in the development of novel therapies, particularly in the field of inflammation and immune-mediated diseases. Aldeyra Therapeutics Inc. successfully conducted pivotal clinical trials for their product candidates, demonstrating positive outcomes and proving their potential efficacy. In addition, they have secured valuable partnerships and collaborations with renowned pharmaceutical organizations, further validating their innovative approach. These achievements solidify Aldeyra Therapeutics Inc.'s position as a promising player in the biotech industry, dedicated to improving patients' lives through groundbreaking advancements.

What is the history and background of the company Aldeyra Therapeutics?

Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapeutic products for immune-mediated diseases. Founded in 2004, Aldeyra initially focused on research and development in the field of inflammation and cancer. Over the years, the company has shifted its focus towards developing novel treatments for conditions such as dry eye disease, allergic conjunctivitis, and Sjögren-Larsson Syndrome. Utilizing their proprietary platform, Aldeyra Therapeutics combines scientific expertise with cutting-edge technology to create potential breakthroughs in disease management. With a strong commitment to improving patient outcomes, Aldeyra Therapeutics Inc. continues to advance its pipeline of therapeutic candidates through rigorous research and clinical trials.

Who are the main competitors of Aldeyra Therapeutics in the market?

Aldeyra Therapeutics Inc faces competition from various companies in the market. Some of its main competitors include Allergan plc, Novartis International AG, and Johnson & Johnson. These companies also operate in the pharmaceutical industry, focusing on developing and marketing therapeutics for various medical conditions. Aldeyra Therapeutics Inc competes with them in terms of research and development, product pipeline, market presence, and commercialization strategies. By constantly innovating and offering unique solutions, Aldeyra Therapeutics Inc aims to stand out and differentiate itself from its competitors in the market.

In which industries is Aldeyra Therapeutics primarily active?

Aldeyra Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Aldeyra Therapeutics?

The business model of Aldeyra Therapeutics Inc focuses on developing and commercializing innovative therapies for the treatment of immune-mediated diseases. Aldeyra Therapeutics utilizes its expertise in the field of inflammation and immune modulation to develop novel therapies that target diseases with high unmet medical needs. The company's research and development efforts aim to advance its pipeline of potential drug candidates, with a particular focus on diseases impacting the eye and skin. By leveraging its proprietary technology platform and strategic collaborations, Aldeyra Therapeutics aims to bring effective treatments to patients suffering from various immune-mediated diseases.

What is the P/E ratio of Aldeyra Therapeutics 2024?

The Aldeyra Therapeutics P/E ratio is -7.29.

What is the P/S ratio of Aldeyra Therapeutics 2024?

The Aldeyra Therapeutics P/S ratio is 10.25.

What is the Quality Investing of Aldeyra Therapeutics?

The Quality Investing for Aldeyra Therapeutics is 4/10.

What is the revenue of Aldeyra Therapeutics 2024?

The expected Aldeyra Therapeutics revenue is 29 M USD.

How high is the profit of Aldeyra Therapeutics 2024?

The expected Aldeyra Therapeutics profit is -40.78 M USD.

What is the business model of Aldeyra Therapeutics

Aldeyra Therapeutics Inc is an American biopharmaceutical company specializing in the development of therapies for the treatment of eye diseases and inflammatory diseases. The company's business model is focused on developing and marketing innovative therapies based on the latest scientific knowledge and technologies. The company invests in research and development of innovative therapeutic approaches, commercialization of these therapies through sales activities and marketing campaigns, and acquisitions or licensing of other companies. Aldeyra Therapeutics' product portfolio currently includes several drug candidates, such as ADX-2191, ADX-1612, ADX-629, and ADX-103, with a high degree of innovation intended for the treatment of various diseases such as acute eye inflammation (conjunctivitis), neuroinflammatory diseases, and orphan diseases (rare diseases). One example is ADX-2191, a medication to be used in the treatment of allergic reactions in the eye. The company also forms targeted partnerships with other companies to develop new drug candidates, such as its collaboration with Elanco, a global leader in animal health, to develop ADX-2191 for the treatment of allergic conjunctivitis in animals. The company's products are marketed through business partners, distribution strategies, and collaborations with healthcare professionals and medical societies. Aldeyra Therapeutics prioritizes complying with the highest quality and ethical standards in the development and marketing of medications, ensuring scientific knowledge and treatment outcomes are communicated in accordance with applicable laws and regulations. Overall, Aldeyra Therapeutics' business model is based on the development of innovative therapeutic approaches for eye and inflammatory diseases, utilizing targeted research and development, strategic partnerships, and targeted sales activities, all while adhering to high quality standards and ethical principles.

What is the Aldeyra Therapeutics dividend?

Aldeyra Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Aldeyra Therapeutics pay dividends?

The dividend cannot currently be calculated for Aldeyra Therapeutics or the company does not pay out a dividend.

What is the Aldeyra Therapeutics ISIN?

The ISIN of Aldeyra Therapeutics is US01438T1060.

What is the Aldeyra Therapeutics WKN?

The WKN of Aldeyra Therapeutics is A111X8.

What is the Aldeyra Therapeutics ticker?

The ticker of Aldeyra Therapeutics is ALDX.

How much dividend does Aldeyra Therapeutics pay?

Over the past 12 months, Aldeyra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aldeyra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aldeyra Therapeutics?

The current dividend yield of Aldeyra Therapeutics is .

When does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aldeyra Therapeutics?

Aldeyra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aldeyra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aldeyra Therapeutics located?

Aldeyra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aldeyra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aldeyra Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Aldeyra Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Aldeyra Therapeutics in the year 2023?

In the year 2023, Aldeyra Therapeutics distributed 0 USD as dividends.

In which currency does Aldeyra Therapeutics pay out the dividend?

The dividends of Aldeyra Therapeutics are distributed in USD.

All fundamentals about Aldeyra Therapeutics

Our stock analysis for Aldeyra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aldeyra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.